Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2015, Article ID 680749, 12 pages
http://dx.doi.org/10.1155/2015/680749
Review Article

TRAIL Modulates the Immune System and Protects against the Development of Diabetes

1Department of Medical, Surgical, and Health Sciences, University of Trieste, Cattinara University Hospital, Strada di Fiume 447, 34100 Trieste, Italy
2Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Via dell’Istria 65, 34100 Trieste, Italy
3Department of Morphology, Surgery, and Experimental Medicine, LTTA Centre, University of Ferrara, Via Fossato di Mortara 66, 44100 Ferrara, Italy

Received 22 December 2014; Accepted 2 February 2015

Academic Editor: Kurt Blaser

Copyright © 2015 Fleur Bossi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. Bernardi, P. Secchiero, and G. Zauli, “State of art and recent developments of anti-cancer strategies based on TRAIL,” Recent Patents on Anti-Cancer Drug Discovery, vol. 7, no. 2, pp. 207–217, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. S. R. Wiley, K. Schooley, P. J. Smolak et al., “Identification and characterization of a new member of the TNF family that induces apoptosis,” Immunity, vol. 3, no. 6, pp. 673–682, 1995. View at Publisher · View at Google Scholar · View at Scopus
  3. V. Nikoletopoulou, M. Markaki, K. Palikaras, and N. Tavernarakis, “Crosstalk between apoptosis, necrosis and autophagy,” Biochimica et Biophysica Acta, vol. 1833, no. 12, pp. 3448–3459, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. S. Jouan-Lanhouet, M. I. Arshad, C. Piquet-Pellorce et al., “TRAIL induces necroptosis involving RIPK1/RIPK3-dependent PARP-1 activation,” Cell Death and Differentiation, vol. 19, no. 12, pp. 2003–2014, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Pan, K. O'Rourke, A. M. Chinnaiyan et al., “The receptor for the cytotoxic ligand TRAIL,” Science, vol. 276, no. 5309, pp. 111–113, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. G. Pan, J. Ni, Y.-F. Wei, G.-I. Yu, R. Gentz, and V. M. Dixit, “An antagonist decoy receptor and a death domain-containing receptor for TRAIL,” Science, vol. 277, no. 5327, pp. 815–818, 1997. View at Publisher · View at Google Scholar · View at Scopus
  7. J. P. Sheridan, S. A. Marsters, R. M. Pitti et al., “Control of TRAIL-induced apoptosis by a family of signaling and decoy receptors,” Science, vol. 277, no. 5327, pp. 818–821, 1997. View at Publisher · View at Google Scholar · View at Scopus
  8. G. S. Wu, T. F. Burns, E. R. McDonald III et al., “KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene,” Nature Genetics, vol. 17, no. 2, pp. 141–143, 1997. View at Publisher · View at Google Scholar · View at Scopus
  9. D. Milani, G. Zauli, E. Rimondi et al., “Tumour necrosis factor-related apoptosis-inducing ligand sequentially activates pro-survival and pro-apoptotic pathways in SK-N-MC neuronal cells,” Journal of Neurochemistry, vol. 86, no. 1, pp. 126–135, 2003. View at Publisher · View at Google Scholar · View at Scopus
  10. M. A. Degli-Esposti, P. J. Smolak, H. Walczak et al., “Cloning and characterization of TRAIL-R3, a novel member of the emerging TRAIL receptor family,” The Journal of Experimental Medicine, vol. 186, no. 7, pp. 1165–1170, 1997. View at Publisher · View at Google Scholar · View at Scopus
  11. M. A. Degli-Esposti, W. C. Dougall, P. J. Smolak, J. Y. Waugh, C. A. Smith, and R. G. Goodwin, “The novel receptor TRAIL-R4 induces NF-κB and protects against TRAIL- mediated apoptosis, yet retains an incomplete death domain,” Immunity, vol. 7, no. 6, pp. 813–820, 1997. View at Publisher · View at Google Scholar · View at Scopus
  12. S. A. Marsters, J. P. Sheridan, R. M. Pitti et al., “A novel receptor for Apo2L/TRAIL contains a truncated death domain,” Current Biology, vol. 7, no. 12, pp. 1003–1006, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. G. Zauli, E. Melloni, S. Capitani, and P. Secchiero, “Role of full-length osteoprotegerin in tumor cell biology,” Cellular and Molecular Life Sciences, vol. 66, no. 5, pp. 841–851, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Cretney, K. Takeda, H. Yagita, M. Glaccum, J. J. Peschon, and M. J. Smyth, “Increased susceptibility to tumor initiation and metastasis in TNF-related apoptosis-inducing ligand-deficient mice,” Journal of Immunology, vol. 168, no. 3, pp. 1356–1361, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. L. M. Sedger, M. B. Glaccum, J. C. Schuh et al., “Characterization of the in vivo function of TNF-α-related apoptosis-inducing ligand, TRAIL/Apo2L, using TRAIL/Apo2L gene-deficient mice,” European Journal of Immunology, vol. 32, no. 8, pp. 2246–2254, 2002. View at Publisher · View at Google Scholar
  16. E. M. Janssen, N. M. Droin, E. E. Lemmens et al., “CD4+ T-cell help controls CD8+ T-cell memory via TRAIL-mediated activation-induced cell death,” Nature, vol. 434, no. 7029, pp. 88–93, 2005. View at Publisher · View at Google Scholar · View at Scopus
  17. K. Takeda, M. J. Smyth, E. Cretney et al., “Critical role for tumor necrosis factor-related apoptosis-inducing ligand in immune surveillance against tumor development,” The Journal of Experimental Medicine, vol. 195, no. 2, pp. 161–169, 2002. View at Publisher · View at Google Scholar · View at Scopus
  18. N. D. Huntington, C. A. J. Vosshenrich, and J. P. di Santo, “Developmental pathways that generate natural-killer-cell diversity in mice and humans,” Nature Reviews Immunology, vol. 7, no. 9, pp. 703–714, 2007. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Nagata, “Apoptosis by death factor,” Cell, vol. 88, no. 3, pp. 355–365, 1997. View at Publisher · View at Google Scholar · View at Scopus
  20. L. A. Tartaglia and D. V. Goeddel, “Two TNF receptors,” Immunology Today, vol. 13, no. 5, pp. 151–153, 1992. View at Publisher · View at Google Scholar · View at Scopus
  21. A. Ashkenazi and R. S. Herbst, “To kill a tumor cell: the potential of proapoptotic receptor agonists,” The Journal of Clinical Investigation, vol. 118, no. 6, pp. 1979–1990, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. A. Ashkenazi, R. C. Pai, S. Fong et al., “Safety and antitumor activity of recombinant soluble Apo2 ligand,” The Journal of Clinical Investigation, vol. 104, no. 2, pp. 155–162, 1999. View at Publisher · View at Google Scholar · View at Scopus
  23. M. Leverkus, H. Walczak, A. McLellan et al., “Maturation of dendritic cells leads to up-regulation of cellular FLICE-inhibitory protein and concomitant down-regulation of death ligand-mediated apoptosis,” Blood, vol. 96, no. 7, pp. 2628–2631, 2000. View at Google Scholar · View at Scopus
  24. P. Secchiero, A. Gonelli, E. Carnevale et al., “TRAIL promotes the survival and proliferation of primary human vascular endothelial cells by activating the Akt and ERK pathways,” Circulation, vol. 107, no. 17, pp. 2250–2256, 2003. View at Publisher · View at Google Scholar · View at Scopus
  25. G. Zauli, S. Sancilio, A. Cataldi, N. Sabatini, D. Bosco, and R. Di Pietro, “PI-3K/Akt and NF-κB/IκBα pathways are activated in Jurkat T cells in response to TRAIL treatment,” Journal of Cellular Physiology, vol. 202, no. 3, pp. 900–911, 2005. View at Publisher · View at Google Scholar · View at Scopus
  26. I. Hunter and G. F. Nixon, “Spatial compartmentalization of tumor necrosis factor (TNF) receptor 1-dependent signaling pathways in human airway smooth muscle cells: lipid rafts are essential for TNF-α-mediated activation of RhoA but dispensable for the activation of the NF-κB and MAPK pathways,” The Journal of Biological Chemistry, vol. 281, no. 45, pp. 34705–34715, 2006. View at Publisher · View at Google Scholar · View at Scopus
  27. J. H. Song, M. C. L. Tse, A. Bellail et al., “Lipid rafts and nonrafts mediate tumor necrosis factor-related apoptosis-inducing ligand-induced apoptotic and nonapoptotic signals in non-small cell lung carcinoma cells,” Cancer Research, vol. 67, no. 14, pp. 6946–6955, 2007. View at Publisher · View at Google Scholar · View at Scopus
  28. B. Toffoli, S. Bernardi, R. Candido, S. Zacchigna, B. Fabris, and P. Secchiero, “TRAIL shows potential cardioprotective activity,” Investigational New Drugs, vol. 30, no. 3, pp. 1257–1260, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. L. M. Sedger, A. Katewa, A. K. Pettersen et al., “Extreme lymphoproliferative disease and fatal autoimmune thrombocytopenia in FasL and TRAIL double-deficient mice,” Blood, vol. 115, no. 16, pp. 3258–3268, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. S.-E. Lamhamedi-Cherradi, S.-J. Zheng, K. A. Maguschak, J. Peschon, and Y. H. Chen, “Defective thymocyte apoptosis and accelerated autoimmune diseases in TRAIL-/- mice,” Nature Immunology, vol. 4, no. 3, pp. 255–260, 2003. View at Publisher · View at Google Scholar · View at Scopus
  31. E. Cretney, A. P. Uldrich, S. P. Berzins, A. Strasser, D. I. Godfrey, and M. J. Smyth, “Normal thymocyte negative selection in TRAIL-deficient mice,” The Journal of Experimental Medicine, vol. 198, no. 3, pp. 491–496, 2003. View at Publisher · View at Google Scholar · View at Scopus
  32. C. M. Walsh, B. G. Wen, A. M. Chinnaiyan, K. O'Rourke, V. M. Dixit, and S. M. Hedrick, “A role for FADD in T cell activation and development,” Immunity, vol. 8, no. 4, pp. 439–449, 1998. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Corazza, G. Brumatti, S. Jakob, A. Villunger, and T. Brunner, “TRAIL and thymocyte apoptosis: not so deadly?” Cell Death and Differentiation, vol. 11, no. 2, pp. S213–S215, 2004. View at Publisher · View at Google Scholar · View at Scopus
  34. S. A. Marsters, R. M. Pitti, C. J. Donahue, S. Ruppert, K. D. Bauer, and A. Ashkenazi, “Activation of apoptosis by Apo-2 ligand is independent of FADD but blocked by CrmA,” Current Biology, vol. 6, no. 6, pp. 750–752, 1996. View at Publisher · View at Google Scholar · View at Scopus
  35. M. J. Martínez-Lorenzo, M. A. Alava, S. Gamen et al., “Involvement of APO2 ligand/TRAIL in activation-induced death of Jurkat and human peripheral blood T cells,” European Journal of Immunology, vol. 28, no. 9, pp. 2714–2725, 1998. View at Publisher · View at Google Scholar
  36. T. Ikeda, S. Hirata, S. Fukushima et al., “Dual effects of TRAIL in suppression of autoimmunity: the inhibition of Th1 cells and the promotion of regulatory T cells,” Journal of Immunology, vol. 185, no. 9, pp. 5259–5267, 2010. View at Publisher · View at Google Scholar · View at Scopus
  37. S. H. Wang, G. H. Chen, Y. Fan, M. Van Antwerp, and J. R. Baker Jr., “Tumor necrosis factor-related apoptosis-inducing ligand inhibits experimental autoimmune thyroiditis by the expansion of CD4+CD25+ regulatory T cells,” Endocrinology, vol. 150, no. 4, pp. 2000–2007, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. S. Sakaguchi, F. Powrie, and R. M. Ransohoff, “Re-establishing immunological self-tolerance in autoimmune disease,” Nature Medicine, vol. 18, no. 1, pp. 54–58, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. C. Lehnert, M. Weiswange, I. Jeremias et al., “TRAIL-receptor costimulation inhibits proximal TCR signaling and suppresses human T cell activation and proliferation,” The Journal of Immunology, vol. 193, no. 8, pp. 4021–4031, 2014. View at Publisher · View at Google Scholar
  40. K. Song, Y. Chen, R. Göke et al., “Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is an inhibitor of autoimmune inflammation and cell cycle progression,” Journal of Experimental Medicine, vol. 191, no. 7, pp. 1095–1103, 2000. View at Publisher · View at Google Scholar · View at Scopus
  41. X. R. Zhang, L. Y. Zhang, S. Devadas, L. Li, A. D. Keegan, and Y. F. Shi, “Reciprocal expression of TRAIL and CD95L in Th1 and Th2 cells: role of apoptosis in T helper subset differentiation,” Cell Death & Differentiation, vol. 10, no. 2, pp. 203–210, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. A. I. Roberts, S. Devadas, X. Zhang et al., “The role of activation-induced cell death in the differentiation of T-helper-cell subsets,” Immunologic Research, vol. 28, no. 3, pp. 285–293, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. A. Bosque, J. Pardo, M. J. Martínez-Lorenzo et al., “Human CD8+ T cell blasts are more sensitive than CD4+ T cell blasts to regulation by APO2L/TRAIL,” European Journal of Immunology, vol. 35, no. 6, pp. 1812–1821, 2005. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Bosque, J. I. Aguiló, M. Del Rey et al., “Cell cycle regulation by FasL and Apo2L/TRAIL in human T-cell blasts. Implications for autoimmune lymphoproliferative syndromes,” Journal of Leukocyte Biology, vol. 84, no. 2, pp. 488–498, 2008. View at Publisher · View at Google Scholar · View at Scopus
  45. J. D. Lünemann, S. Waiczies, S. Ehrlich et al., “Death ligand TRAIL induces no apoptosis but inhibits activation of human (auto)antigen-specific T cells,” Journal of Immunology, vol. 168, no. 10, pp. 4881–4888, 2002. View at Publisher · View at Google Scholar · View at Scopus
  46. J. Ursini-Siegel, W. Zhang, A. Altmeyer et al., “Trail/Apo-2 ligand induces primary plasma cell apoptosis,” The Journal of Immunology, vol. 169, no. 10, pp. 5505–5513, 2002. View at Publisher · View at Google Scholar · View at Scopus
  47. N. Kayagaki, N. Yamaguchi, M. Abe et al., “Suppression of antibody production by TNF-related apoptosis-inducing ligand (TRAIL),” Cellular Immunology, vol. 219, no. 2, pp. 82–91, 2002. View at Publisher · View at Google Scholar · View at Scopus
  48. S. A. Renshaw, J. S. Parmar, V. Singleton et al., “Acceleration of human neutrophil apoptosis by TRAIL,” Journal of Immunology, vol. 170, no. 2, pp. 1027–1033, 2003. View at Publisher · View at Google Scholar · View at Scopus
  49. S. Bernardi, D. Milani, B. Fabris, P. Secchiero, and G. Zauli, “TRAIL as biomarker and potential therapeutic tool for cardiovascular diseases,” Current Drug Targets, vol. 13, no. 9, pp. 1215–1221, 2012. View at Publisher · View at Google Scholar · View at Scopus
  50. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  51. P. Secchiero, F. Corallini, M. G. Di Iasio, A. Gonelli, E. Barbarotto, and G. Zauli, “TRAIL counteracts the proadhesive activity of inflammatory cytokines in endothelial cells by down-modulating CCL8 and CXCL10 chemokine expression and release,” Blood, vol. 105, no. 9, pp. 3413–3419, 2005. View at Publisher · View at Google Scholar · View at Scopus
  52. P. Secchiero, R. Candido, F. Corallini et al., “Systemic tumor necrosis factor-related apoptosis-inducing ligand delivery shows antiatherosclerotic activity in apolipoprotein E-null diabetic mice,” Circulation, vol. 114, no. 14, pp. 1522–1530, 2006. View at Publisher · View at Google Scholar · View at Scopus
  53. B. A. Di Bartolo, J. Chan, M. R. Bennett et al., “TNF-related apoptosis-inducing ligand (TRAIL) protects against diabetes and atherosclerosis in Apoe −/− mice,” Diabetologia, vol. 54, no. 12, pp. 3157–3167, 2011. View at Publisher · View at Google Scholar · View at Scopus
  54. P. J. Roberts-Thomson, M. W. Jackson, and T. P. Gordon, “A seminal monograph: Mackay and Burnet's Autoimmune diseases,” Medical Journal of Australia, vol. 196, no. 1, pp. 74–76, 2012. View at Publisher · View at Google Scholar · View at Scopus
  55. J. Diana, Y. Simoni, L. Furio et al., “Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes,” Nature Medicine, vol. 19, no. 1, pp. 65–73, 2013. View at Publisher · View at Google Scholar · View at Scopus
  56. K. Koczwara, E. Bonifacio, and A.-G. Ziegler, “Transmission of maternal islet antibodies and risk of autoimmune diabetes in offspring of mothers with type 1 diabetes,” Diabetes, vol. 53, no. 1, pp. 1–4, 2004. View at Publisher · View at Google Scholar · View at Scopus
  57. T. P. Di Lorenzo, M. Peakman, and B. O. Roep, “Translational mini-review series on type 1 diabetes: systematic analysis of T cell epitopes in autoimmune diabetes,” Clinical & Experimental Immunology, vol. 148, no. 1, pp. 1–16, 2007. View at Publisher · View at Google Scholar · View at Scopus
  58. E. E. Hamilton-Williams, S. E. Palmer, B. Charlton, and R. M. Slattery, “Beta cell MHC class I is a late requirement for diabetes,” Proceedings of the National Academy of Sciences of the United States of America, vol. 100, no. 11, pp. 6688–6693, 2003. View at Publisher · View at Google Scholar · View at Scopus
  59. K. Buschard, S. Madsbad, and J. Rygaard, “Depressed suppressor cell activity in patients with newly diagnosed insulin-dependent diabetes mellitus,” Clinical and Experimental Immunology, vol. 41, no. 1, pp. 25–32, 1980. View at Google Scholar · View at Scopus
  60. M.-G. Roncarolo and M. Battaglia, “Regulatory T-cell immunotherapy for tolerance to self antigens and alloantigens in humans,” Nature Reviews Immunology, vol. 7, no. 8, pp. 585–598, 2007. View at Publisher · View at Google Scholar · View at Scopus
  61. B. O. Roep, “The role of T-cells in the pathogenesis of Type 1 diabetes: from cause to cure,” Diabetologia, vol. 46, no. 3, pp. 305–321, 2003. View at Google Scholar · View at Scopus
  62. G. S. Eisenbarth, “Type I diabetes mellitus. A chronic autoimmune disease,” The New England Journal of Medicine, vol. 314, no. 21, pp. 1360–1368, 1986. View at Publisher · View at Google Scholar · View at Scopus
  63. S. Martin, D. Wolf-Eichbaum, G. Duinkerken et al., “Development of type 1 diabetes despite severe hereditary B-cell deficiency,” The New England Journal of Medicine, vol. 345, no. 14, pp. 1036–1040, 2001. View at Publisher · View at Google Scholar · View at Scopus
  64. T. L. van Belle, K. T. Coppieters, and M. G. von Herrath, “Type 1 diabetes: etiology, immunology, and therapeutic strategies,” Physiological Reviews, vol. 91, no. 1, pp. 79–118, 2011. View at Publisher · View at Google Scholar · View at Scopus
  65. S. Bernardi, A. Norcio, B. Toffoli, G. Zauli, and P. Secchiero, “Potential role of TRAIL in the management of autoimmune diabetes mellitus,” Current Pharmaceutical Design, vol. 18, no. 35, pp. 5759–5765, 2012. View at Publisher · View at Google Scholar · View at Scopus
  66. S. E. Lamhamedi-Cherradi, S. Zheng, R. M. Tisch, and Y. H. Chen, “Critical roles of tumor necrosis factor-related apoptosis-inducing ligand in type 1 diabetes,” Diabetes, vol. 52, no. 9, pp. 2274–2278, 2003. View at Publisher · View at Google Scholar · View at Scopus
  67. G. Zauli, B. Toffoli, M. G. Di Iasio, C. Celeghini, B. Fabris, and P. Secchiero, “Treatment with recombinant tumor necrosis factor-related apoptosis-inducing ligand alleviates the severity of streptozotocin-induced diabetes,” Diabetes, vol. 59, no. 5, pp. 1261–1265, 2010. View at Publisher · View at Google Scholar · View at Scopus
  68. G. Tornese, D. Iafusco, L. Monasta et al., “The levels of circulating TRAIL at the onset of type 1 diabetes are markedly decreased in patients with ketoacidosis and with the highest insulin requirement,” Acta Diabetologica, vol. 51, no. 2, pp. 239–246, 2014. View at Publisher · View at Google Scholar · View at Scopus
  69. Q.-S. Mi, D. Ly, S.-E. Lamhamedi-Cherradi et al., “Blockade of tumor necrosis factor-related apoptosis-inducing ligand exacerbates type 1 diabetes in NOD mice,” Diabetes, vol. 52, no. 8, pp. 1967–1975, 2003. View at Publisher · View at Google Scholar · View at Scopus
  70. L. J. Appleman, D. Tzachanis, T. Grader-Beck, A. A. F. L. van Puijenbroek, and V. A. Boussiotis, “Helper T cell anergy: from biochemistry to cancer pathophysiology and therapeutics,” Journal of Molecular Medicine, vol. 78, no. 12, pp. 673–683, 2000. View at Publisher · View at Google Scholar · View at Scopus
  71. S. Kang, S.-Y. Park, H.-J. Lee, and Y. H. Yoo, “TRAIL upregulates decoy receptor 1 and mediates resistance to apoptosis in insulin-secreting INS-1 cells,” Biochemical and Biophysical Research Communications, vol. 396, no. 3, pp. 731–735, 2010. View at Publisher · View at Google Scholar · View at Scopus
  72. E. Dirice, S. Kahraman, G. O. Elpek et al., “TRAIL and DcR1 expressions are differentially regulated in the pancreatic islets of STZ- versus CY-applied NOD mice,” Experimental Diabetes Research, vol. 2011, Article ID 625813, 11 pages, 2011. View at Publisher · View at Google Scholar · View at Scopus
  73. S. Kang, E.-J. Park, Y. Joe et al., “Systemic delivery of TNF-Related Apoptosis-Inducing Ligand (TRAIL) elevates levels of tissue inhibitor of metalloproteinase-1 (TIMP-1) and prevents type 1 diabetes in nonobese diabetic mice,” Endocrinology, vol. 151, no. 12, pp. 5638–5646, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. P. R. Maxwell, P. M. Timms, S. Chandran, and D. Gordon, “Peripheral blood level alterations of TIMP-1, MMP-2 and MMP-9 in patients with Type 1 diabetes,” Diabetic Medicine, vol. 18, no. 10, pp. 777–780, 2001. View at Publisher · View at Google Scholar · View at Scopus
  75. F. J. Descamps, E. Martens, F. Ballaux, K. Geboes, and G. Opdenakker, “In vivo activation of gelatinase B/MMP-9 by trypsin in acute pancreatitis is a permissive factor in streptozotocin-induced diabetes,” Journal of Pathology, vol. 204, no. 5, pp. 555–561, 2004. View at Publisher · View at Google Scholar · View at Scopus
  76. M. Xue, P. J. Thompson, R. Clifton-Bligh, G. Fulcher, E. D. M. Gallery, and C. Jackson, “Leukocyte matrix metalloproteinase-9 is elevated and contributes to lymphocyte activation in type I diabetes,” International Journal of Biochemistry and Cell Biology, vol. 37, no. 11, pp. 2406–2416, 2005. View at Publisher · View at Google Scholar · View at Scopus
  77. X. Han, Y. Sun, S. Scott, and D. Bleich, “Tissue inhibitor of metalloproteinase-1 prevents cytokine-mediated dysfunction and cytotoxicity in pancreatic islets and β-cells,” Diabetes, vol. 50, no. 5, pp. 1047–1055, 2001. View at Publisher · View at Google Scholar · View at Scopus
  78. R. A. Defronzo, “Banting lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus,” Diabetes, vol. 58, no. 4, pp. 773–795, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. W. Ebstein, “Zur therapie des diabetes mellitus, insbesondere uber die Anwendung des salicylsauren natron bei demselben,” Berliner Klinische Wochenschrift, vol. 13, pp. 337–340, 1876. View at Google Scholar
  80. J. C. Pickup and M. A. Crook, “Is type II diabetes mellitus a disease of the innate immune system?” Diabetologia, vol. 41, no. 10, pp. 1241–1248, 1998. View at Publisher · View at Google Scholar · View at Scopus
  81. W. Yang, J. Lu, J. Weng et al., “Prevalence of diabetes among men and women in China,” The New England Journal of Medicine, vol. 362, no. 12, pp. 1090–1101, 2010. View at Publisher · View at Google Scholar · View at Scopus
  82. P. A. Tataranni and E. Ortega, “A burning question: does an adipokine-induced activation of the immune system mediate the effect of overnutrition on type 2 diabetes?” Diabetes, vol. 54, no. 4, pp. 917–927, 2005. View at Publisher · View at Google Scholar · View at Scopus
  83. G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, “Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance,” Science, vol. 259, no. 5091, pp. 87–91, 1993. View at Publisher · View at Google Scholar · View at Scopus
  84. G. S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M. F. White, and B. M. Spiegelman, “IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance,” Science, vol. 271, no. 5249, pp. 665–668, 1996. View at Publisher · View at Google Scholar · View at Scopus
  85. M. Visser, L. M. Bouter, G. M. McQuillan, M. H. Wener, and T. B. Harris, “Elevated C-reactive protein levels in overweight and obese adults,” The Journal of the American Medical Association, vol. 282, no. 22, pp. 2131–2135, 1999. View at Publisher · View at Google Scholar · View at Scopus
  86. D. J. Freeman, J. Norrie, M. J. Caslake et al., “C-reactive protein is an independent predictor of risk for the development of diabetes in the west of Scotland coronary prevention study,” Diabetes, vol. 51, no. 5, pp. 1596–1600, 2002. View at Publisher · View at Google Scholar · View at Scopus
  87. F. B. Hu, J. B. Meigs, T. Y. Li, N. Rifai, and J. E. Manson, “Inflammatory markers and risk of developing type 2 diabetes in women,” Diabetes, vol. 53, no. 3, pp. 693–700, 2004. View at Publisher · View at Google Scholar · View at Scopus
  88. S. Bernardi, B. Fabris, M. Thomas et al., “Osteoprotegerin increases in metabolic syndrome and promotes adipose tissue proinflammatory changes,” Molecular and Cellular Endocrinology, vol. 394, no. 1-2, pp. 13–20, 2014. View at Publisher · View at Google Scholar
  89. H. Sell, C. Habich, and J. Eckel, “Adaptive immunity in obesity and insulin resistance,” Nature Reviews Endocrinology, vol. 8, no. 12, pp. 709–716, 2012. View at Publisher · View at Google Scholar · View at Scopus
  90. S. Cinti, G. Mitchell, G. Barbatelli et al., “Adipocyte death defines macrophage localization and function in adipose tissue of obese mice and humans,” Journal of Lipid Research, vol. 46, no. 11, pp. 2347–2355, 2005. View at Publisher · View at Google Scholar · View at Scopus
  91. K. J. Strissel, Z. Stancheva, H. Miyoshi et al., “Adipocyte death, adipose tissue remodeling, and obesity complications,” Diabetes, vol. 56, no. 12, pp. 2910–2918, 2007. View at Publisher · View at Google Scholar · View at Scopus
  92. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante Jr., “Obesity is associated with macrophage accumulation in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003. View at Publisher · View at Google Scholar · View at Scopus
  93. R. S. Lindsay, D. J. Wake, S. Nair et al., “Subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians,” The Journal of Clinical Endocrinology & Metabolism, vol. 88, no. 6, pp. 2738–2744, 2003. View at Publisher · View at Google Scholar · View at Scopus
  94. H. Masuzaki, J. Paterson, H. Shinyama et al., “A transgenic model of visceral obesity and the metabolic syndrome,” Science, vol. 294, no. 5549, pp. 2166–2170, 2001. View at Publisher · View at Google Scholar · View at Scopus
  95. H. Xu, G. T. Barnes, Q. Yang et al., “Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1821–1830, 2003. View at Publisher · View at Google Scholar · View at Scopus
  96. J. I. Odegaard and A. Chawla, “Connecting type 1 and type 2 diabetes through innate immunity,” Cold Spring Harbor Perspectives in Medicine, vol. 2, no. 3, Article ID a007724, 2012. View at Google Scholar · View at Scopus
  97. S. P. Weisberg, D. Hunter, R. Huber et al., “CCR2 modulates inflammatory and metabolic effects of high-fat feeding,” Journal of Clinical Investigation, vol. 116, no. 1, pp. 115–124, 2006. View at Publisher · View at Google Scholar · View at Scopus
  98. H. Kanda, S. Tateya, Y. Tamori et al., “MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity,” The Journal of Clinical Investigation, vol. 116, no. 6, pp. 1494–1505, 2006. View at Publisher · View at Google Scholar · View at Scopus
  99. S. Winer, Y. Chan, G. Paltser et al., “Normalization of obesity-associated insulin resistance through immunotherapy,” Nature Medicine, vol. 15, no. 8, pp. 921–929, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. M. Saberi, N.-B. Woods, C. de Luca et al., “Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice,” Cell Metabolism, vol. 10, no. 5, pp. 419–429, 2009. View at Publisher · View at Google Scholar · View at Scopus
  101. S. Bernardi, G. Zauli, C. Tikellis et al., “TNF-related apoptosis-inducing ligand significantly attenuates metabolic abnormalities in high-fat-fed mice reducing adiposity and systemic inflammation,” Clinical Science (London, England : 1979), vol. 123, no. 9, pp. 547–555, 2012. View at Publisher · View at Google Scholar · View at Scopus
  102. S. Bernardi, C. Tikellis, R. Candido et al., “ACE2 deficiency shifts energy metabolism towards glucose utilization,” Metabolism, vol. 64, no. 3, pp. 406–415, 2015. View at Publisher · View at Google Scholar
  103. B. Toffoli, S. Bernardi, R. Candido et al., “Osteoprotegerin induces morphological and functional alterations in mouse pancreatic islets,” Molecular and Cellular Endocrinology, vol. 331, no. 1, pp. 136–142, 2011. View at Publisher · View at Google Scholar · View at Scopus
  104. C. Pitombo, E. P. Araújo, C. T. De Souza, J. C. Pareja, B. Geloneze, and L. A. Velloso, “Amelioration of diet-induced diabetes mellitus by removal of visceral fat,” Journal of Endocrinology, vol. 191, no. 3, pp. 699–706, 2006. View at Publisher · View at Google Scholar · View at Scopus
  105. H. H. Harith, M. J. Morris, and M. M. Kavurma, “On the TRAIL of obesity and diabetes,” Trends in Endocrinology and Metabolism, vol. 24, no. 11, pp. 578–587, 2013. View at Publisher · View at Google Scholar · View at Scopus